Why I’d sell this FTSE 100 stock and buy this small-cap share

G A Chester sees the valuation of this flying FTSE 100 stock as far too dizzy, but finds good value on offer at a small-cap sector peer.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 stock AstraZeneca (LSE: AZN) has smashed the index’s performance this year. The pharmaceuticals giant has risen an impressive 19%, compared with the Footsie’s miserable 22% decline.

However, there’s one big reason I’d sell AZN today. It’s specific to the company. I’m actually keen on the healthcare sector generally. Indeed, Alliance Pharma (LSE: APH) is a stock I’d happily buy right now.

Here, I’ll compare and contrast AZN and APH. You’ll be able to see exactly why I’m bearish on the former and bullish on the latter.

FTSE 100 stock vs AIM small-cap

One big difference between AZN and APH is their sizes. The former generated $24bn revenue last year and has a market capitalisation of £118bn. For APH, the numbers are £136m and £393m.

Another big difference is their business models. AZN is a research-led drugs developer. APH acquires and exploits established cash-generative assets (from companies like AZN).

Despite their different sizes and business models, both have wide geographical diversification. AZN is a bit more diversified, with the US its biggest country market (33% of sales). For APH, it’s the UK/Republic of Ireland (59%).

Similarly, APH is a bit more reliant on its top four sellers (46% of sales) than AZN (37%). On the other hand, while AZN is a pure-play pharma business, APH is diversified across consumer healthcare brands (55% of sales) and prescription medicines (45%).

On the above considerations alone, I don’t think it’s possible to say one business is an inherently superior investment to the other.

Valuation conundrum

It’s become the norm for companies to headline ‘core’ earnings per share (EPS). Or ‘underlying’, or ‘adjusted’, or ‘normalised’ EPS. Anything but the statutory number! Almost invariably, companies’ definitions of core EPS produce a higher number than their statutory EPS.

You might expect companies on the lightly-regulated AIM market, like APH, to have a tendency to conjure more flattering core numbers than blue-chip FTSE 100 stocks like AZN. However, the first table below, with the always-highly-flattering core EPS numbers, is AZN. The second, with the far-more-reasonable-looking core/statutory differences, is APH.

 AZN

2015

2016

2017

2018

2019

Average

Core EPS (¢)

426

431

428

346

350

396

Statutory EPS (¢)

223

277

237

170

103

202

Statutory as % of core EPS

52

64

55

49

29

51

 

 APH

2015

2016

2017

2018

2019

Average

Core EPS (p)

3.52

3.85

4.06

4.54

5.09

4.21

Statutory EPS (p)

4.65

3.85

6.10

3.69

4.80

4.62

Statutory as % of core EPS

132

100

150

81

94

109

In my experience, routinely accepting a company’s core EPS at face value doesn’t pay investors in the long run. As such, a company with a wide gulf between core and statutory EPS presents a valuation conundrum.

AZN: overvalued FTSE 100 stock?

At a share price of 9,004p, AZN’s price-to-earnings (P/E) ratio is an eye-watering 54, based on its five-year average statutory EPS. Now, while I reject AZN’s policy of including non-core asset sales in its core EPS as a nonsense, I think some adjustments are legitimate. However, even being as generous as possible, I can only get the P/E down to 35. And even on AZN’s core numbers, the P/E of 28 is still far too rich, in my book.

Meanwhile, at a share price of 74p, APH’s P/E is 16, based on its five-year average statutory EPS, and below 18 on its core EPS. Whichever way I look at it, I see APH as attractively valued on a mid-teens P/E. This is why I rate the stock a ‘buy’.

By contrast, I see AZN’s valuation as somewhere between far too rich (P/E 28) and grossly overvalued (P/E 54). This is why I rate it a ‘sell’.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended Alliance Pharma. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »